


> d 13  
 L3 HAS NO ANSWERS  
 L3 STR



NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC 18 10  
 NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

=> s 13 ful  
 FULL SEARCH INITIATED 15:03:31 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 3662 TO ITERATE

100.0% PROCESSED 3662 ITERATIONS 583 ANSWERS  
 SEARCH TIME: 00.00.01

L5 583 SEA SSS FUL L3

=> fil caplus  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 168.70 168.91

FILE 'CAPLUS' ENTERED AT 15:03:34 ON 23 FEB 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2006 VOL 144 ISS 9  
 FILE LAST UPDATED: 22 Feb 2006 (20060222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15

L6 5 L5

=> d bib 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:485162 CAPLUS  
DN 141:38534  
TI Preparation of aromatic sulfone hydroxamic acid metalloprotease inhibitors  
IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.;  
Carroll, Jeffrey N.; Decrescenzo, Gary A.; Fobian, Yvette M.; Freskos,  
John N.; Getman, Daniel P.; McDonald, Joseph J.; Li, Madeleine H.;  
Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Mischke,  
Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.;  
Vernier, William F.; Villamil, Clara I.  
PA Pharmacia Corporation, USA  
SO U.S., 403 pp., Cont.-in-part of U.S. Ser. No. 311,837.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6750228	B1	20040615	US 2000-570731	20000512
	US 2001014688	A1	20010816	US 1998-191129	19981113
	US 2001039287	A1	20011108	US 1999-256948	19990224
	CA 2372934	AA	20001123	CA 2000-2372934	20000515
	WO 2000069821	A1	20001123	WO 2000-US6719	20000515
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1183239	A1	20020306	EP 2000-930088	20000515
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010562	A	20030610	BR 2000-10562	20000515
	JP 2003520196	T2	20030702	JP 2000-618238	20000515
	AU 766792	B2	20031023	AU 2000-47970	20000515
	NZ 515217	A	20040430	NZ 2000-515217	20000515
	US 2002177588	A1	20021128	US 2001-954451	20010917
	US 6750233	B2	20040615		
	ZA 2001009006	A	20021202	ZA 2001-9006	20011031
	NO 2001005543	A	20020110	NO 2001-5543	20011113
	US 2003073718	A1	20030417	US 2001-989943	20011121
	US 6683093	B2	20040127		
	US 2004209914	A1	20041021	US 2003-730403	20031208
	US 2004235818	A1	20041125	US 2003-747796	20031229
PRAI	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-101080P	P	19980918		
	US 1999-256948	B2	19990224		
	US 1999-311837	A2	19990514		
	US 1998-95501P	P	19980806		
	US 1998-186410	B2	19981105		
	US 1998-191129	B2	19981113		
	US 2000-570731	A	20000512		
	WO 2000-US6719	W	20000515		
	US 2001-989943	A3	20011121		

OS MARPAT 141:38534

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:300620 CAPLUS

DN 138:321016

TI Preparation of aromatic sulfone hydroxamic acids and their use as protease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; Decrescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Li, Madeleine H.; Hockerman, Susan L.; Howard, Carol Pearcy; Kolodziej, Steve A.; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Kassab, Darren J.

PA Pharmacia Corp., USA

SO U.S. Pat. Appl. Publ., 99 pp., Cont. of U.S. Ser. No. 570,731.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003073718	A1	20030417	US 2001-989943	20011121
	US 6683093	B2	20040127		
	US 6750228	B1	20040615	US 2000-570731	20000512
	CA 2467565	AA	20030605	CA 2002-2467565	20021119
	WO 2003045944	A1	20030605	WO 2002-US37093	20021119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002352795	A1	20030610	AU 2002-352795	20021119
	BR 2002014450	A	20040914	BR 2002-14450	20021119
	EP 1472244	A1	20041103	EP 2002-789749	20021119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005514375	T2	20050519	JP 2003-547394	20021119
	US 2004209914	A1	20041021	US 2003-730403	20031208
PRAI	US 2000-570731	A2	20000512		
	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-101080P	P	19980918		
	US 1999-256948	B2	19990224		
	US 1999-311837	A2	19990514		
	US 2001-989943	A	20011121		
	WO 2002-US37093	W	20021119		

OS MARPAT 138:321016

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:824220 CAPLUS

DN 134:17399

TI Aromatic sulfone hydroxamic acid metalloprotease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; Decrescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Stephen A.; Li, Madeleine Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.;

Vernier, William F.; Villamil, Clara I.  
PA G.D. Searle and Co., USA  
SO PCT Int. Appl., 616 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000069821	A1	20001123	WO 2000-US6719	20000515
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6750228	B1	20040615	US 2000-570731	20000512
	CA 2372934	AA	20001123	CA 2000-2372934	20000515
	EP 1183239	A1	20020306	EP 2000-930088	20000515
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010562	A	20030610	BR 2000-10562	20000515
	JP 2003520196	T2	20030702	JP 2000-618238	20000515
	AU 766792	B2	20031023	AU 2000-47970	20000515
	NZ 515217	A	20040430	NZ 2000-515217	20000515
	ZA 2001009006	A	20021202	ZA 2001-9006	20011031
	NO 2001005543	A	20020110	NO 2001-5543	20011113
PRAI	US 1999-311837	A	19990514		
	US 2000-570731	A	20000512		
	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-101080P	P	19980918		
	US 1999-256948	B2	19990224		
	WO 2000-US6719	W	20000515		

OS MARPAT 134:17399

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:608722 CAPLUS

DN 133:193079

TI Preparation of arylsulfonylheterocyclhydroxamic acids and related compounds as matrix metalloprotease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; De Crescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hanson, Gunnar J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Li, Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Rao, Shashidhar N.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 851 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050396	A1	20000831	WO 2000-US2518	20000222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,				

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2001039287 A1 20011108 US 1999-256948 19990224  
 CA 2371876 AA 20000831 CA 2000-2371876 20000222  
 AU 2000034785 A5 20000914 AU 2000-34785 20000222  
 EP 1230219 A1 20020814 EP 2000-913317 20000222  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 BR 2000008491 A 20020917 BR 2000-8491 20000222  
 JP 2002537378 T2 20021105 JP 2000-600979 20000222  
 NZ 513648 A 20040227 NZ 2000-513648 20000222  
 NO 2001003963 A 20011023 NO 2001-3963 20010815  
 ZA 2001006780 A 20020816 ZA 2001-6780 20010816  
 US 2002177588 A1 20021128 US 2001-954451 20010917  
 US 6750233 B2 20040615

PRAI US 1999-256948 A 19990224  
 US 1997-66007P P 19971114  
 US 1998-95347P P 19980804  
 US 1998-95501P P 19980806  
 US 1998-101080P P 19980918  
 WO 2000-US2518 W 20000222

OS MARPAT 133:193079

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1999:350651 CAPLUS

DN 131:18929

TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related  
 compounds as matrix metalloprotease inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary  
 A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman,  
 Daniel P.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 840 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925687	A1	19990527	WO 1998-US23242	19981112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2306460	AA	19990527	CA 1998-2306460	19981112
	AU 9913732	A1	19990607	AU 1999-13732	19981112
	AU 756150	B2	20030102		
	BR 9814643	A	20001003	BR 1998-14643	19981112
	EP 1042290	A1	20001011	EP 1998-957485	19981112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001523662	T2	20011127	JP 2000-521071	19981112
	NZ 503485	A	20021025	NZ 1998-503485	19981112
	RU 2250105	C2	20050420	RU 2000-115948	19981112
	ZA 9810412	A	19991209	ZA 1998-10412	19981113
	US 2001014688	A1	20010816	US 1998-191129	19981113
	NO 2000002469	A	20000712	NO 2000-2469	20000512

US 6541489	B1	20030401	US 2000-554082	20000731
US 2002177588	A1	20021128	US 2001-954451	20010917
US 6750233	B2	20040615		
US 2004048852	A1	20040311	US 2003-337942	20030107
US 6890937	B2	20050510		
PRAI US 1997-66007P	P	19971114		
US 1998-95347P	P	19980804		
US 1998-95501P	P	19980806		
US 1998-101080P	P	19980918		
WO 1998-US23242	W	19981112		
US 1999-256948	B3	19990224		
US 2000-554082	A3	20000731		
OS MARPAT 131:18929				
RE.CNT 6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD			
	ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=>

AN 1999:350651 CAPLUS  
 DN 131:18929  
 TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors  
 IN Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.; De Crescenzo, Gary A.; Villamil, Clara I.; McDonald, Joseph J.; Freskos, John N.; Getman, Daniel P.  
 PA G.D. Searle and Co., USA  
 SO PCT Int. Appl., 840 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925687	A1	19990527	WO 1998-US23242	19981112
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2306460	AA	19990527	CA 1998-2306460	19981112
	AU 9913732	A1	19990607	AU 1999-13732	19981112
	AU 756150	B2	20030102		
	BR 9814643	A	20001003	BR 1998-14643	19981112
	EP 1042290	A1	20001011	EP 1998-957485	19981112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001523662	T2	20011127	JP 2000-521071	19981112
	NZ 503485	A	20021025	NZ 1998-503485	19981112
	RU 2250105	C2	20050420	RU 2000-115948	19981112
	ZA 9810412	A	19991209	ZA 1998-10412	19981113
	US 2001014688	A1	20010816	US 1998-191129	19981113
	NO 2000002469	A	20000712	NO 2000-2469	20000512
	US 6541489	B1	20030401	US 2000-554082	20000731
	US 2002177588	A1	20021128	US 2001-954451	20010917
	US 6750233	B2	20040615		
	US 2004048852	A1	20040311	US 2003-337942	20030107
	US 6890937	B2	20050510		
PRAI	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-95501P	P	19980806		
	US 1998-101080P	P	19980918		
	WO 1998-US23242	W	19981112		
	US 1999-256948	B3	19990224		
	US 2000-554082	A3	20000731		
OS	MARPAT 131:18929				
IT	226388-70-1P 226389-43-1P 226390-85-8P				
	226390-87-0P 226390-99-4P 226391-01-1P				
	226391-06-6P 226391-08-8P 226391-12-4P				
	226391-13-5P 226391-28-2P 226391-75-9P				
	226391-78-2P 226391-80-6P 226391-82-8P				
	226391-84-0P 226391-86-2P 226391-88-4P				
	226392-04-7P 226392-06-9P 226392-08-1P				
	226392-10-5P 226392-12-7P 226392-14-9P				
	226392-16-1P 226392-34-3P 226392-36-5P				
	226392-52-5P 226392-54-7P 226392-56-9P				
	226392-58-1P 226392-60-5P 226392-62-7P				
	226392-64-9P 226392-66-1P 226392-68-3P				
	226392-70-7P 226392-72-9P 226392-74-1P				
	226392-76-3P 226392-78-5P 226392-80-9P				

AN 2000:608722 CAPLUS  
 DN 133:193079  
 TI Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors  
 IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; De Crescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hanson, Gunnar J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Li, Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Rao, Shashidhar N.  
 PA G.D. Searle and Co., USA  
 SO PCT Int. Appl., 851 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000050396	A1	20000831	WO 2000-US2518	20000222
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2001039287	A1	20011108	US 1999-256948	19990224
	CA 2371876	AA	20000831	CA 2000-2371876	20000222
	AU 2000034785	A5	20000914	AU 2000-34785	20000222
	EP 1230219	A1	20020814	EP 2000-913317	20000222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000008491	A	20020917	BR 2000-8491	20000222
	JP 2002537378	T2	20021105	JP 2000-600979	20000222
	NZ 513648	A	20040227	NZ 2000-513648	20000222
	NO 2001003963	A	20011023	NO 2001-3963	20010815
	ZA 2001006780	A	20020816	ZA 2001-6780	20010816
	US 2002177588	A1	20021128	US 2001-954451	20010917
	US 6750233	B2	20040615		
PRAI	US 1999-256948	A	19990224		
	US 1997-66007P	P	19971114		
	US 1998-95347P	P	19980804		
	US 1998-95501P	P	19980806		
	US 1998-101080P	P	19980918		
	WO 2000-US2518	W	20000222		
OS	MARPAT 133:193079				
IT	226388-70-1P 226389-43-1P 226390-85-8P				
	226390-87-0P 226390-99-4P 226391-01-1P				
	226391-06-6P 226391-08-8P 226391-12-4P				
	226391-13-5P 226391-28-2P 226391-75-9P				
	226391-78-2P 226391-80-6P 226391-82-8P				
	226391-84-0P 226391-86-2P 226391-88-4P				
	226392-04-7P 226392-06-9P 226392-08-1P				
	226392-10-5P 226392-12-7P 226392-14-9P				
	226392-16-1P 226392-34-3P 226392-36-5P				
	226392-52-5P 226392-54-7P 226392-56-9P				
	226392-58-1P 226392-60-5P 226392-62-7P				
	226392-64-9P 226392-66-1P 226392-68-3P				
	226392-70-7P 226392-72-9P 226392-74-1P				
	226392-76-3P 226392-78-5P 226392-80-9P				
	226392-82-1P 226392-84-3P 226392-86-5P				
	226392-88-7P 226392-90-1P 226392-92-3P				




226392-94-5P 226392-96-7P 226392-98-9P  
 226393-00-6P 226393-02-8P 226393-04-0P  
 226395-04-6P 226395-06-8P 226395-08-0P  
 226395-10-4P 226395-12-6P 226395-13-7P  
 226395-14-8P 226395-16-0P 226395-17-1P  
 226395-18-2P 226395-19-3P 226395-21-7P  
 226395-22-8P 226395-24-0P 226395-25-1P  
 226395-26-2P 226395-27-3P 226395-28-4P  
 226395-29-5P 226395-30-8P 226395-31-9P  
 226395-32-0P 226395-33-1P 226395-35-3P  
 226395-36-4P 226395-37-5P 226395-38-6P  
 226395-39-7P 226395-40-0P 226395-41-1P  
 226395-44-4P 226395-45-5P 226395-47-7P  
 226395-49-9P 226395-50-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonylheterocyclylhydroxamic acids and related compds. as matrix metalloprotease inhibitors)

RN 226388-70-1 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-(4-butoxy-1-piperidiny)phenyl]sulfonyl]tetrahydro-N-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226389-43-1 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-(1,3-benzodioxol-5-yloxy)-1-piperidiny]phenyl]sulfonyl]tetrahydro-N-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226390-85-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-hydroxy-4-(phenylmethyl)-1-piperidiny]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226390-84-7

•



CMF C2 H F3 O2



CN

CMF C22 H33 N3 O6 S



CMF C2 H F3 O2




RN 226390-99-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(phenylmethyl)-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226390-98-3


CMF C24 H30 N2 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226391-01-1 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(4-methyl-1-piperidinyl)phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-00-0


CMF C18 H26 N2 O5 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226391-06-6 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-(4-hydroxy-4-phenyl-1-piperidinyl)phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-05-5


CMF C23 H28 N2 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226391-08-8 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, ethyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-07-7


CMF C20 H28 N2 O7 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 226391-12-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 226391-13-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-12-4


CMF C18 H25 N3 O6 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 226391-28-2 CAPLUS  
 CN 2H-Pyran-4-carboxamide, 4-[[4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 226391-27-1  
 CMF C23 H27 Br N2 O6 S



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 226391-75-9 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(4-morpholinylcarbonyl)-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 226391-74-8  
 CMF C22 H31 N3 O7 S



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 226391-78-2 CAPLUS

CN 4-Piperidinecarboxamide, N-(2-hydroxyethyl)-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-77-1


CMF C20 H29 N3 O7 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226391-80-6 CAPLUS

CN 4-Piperidinecarboxamide, N-(3-aminopropyl)-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-79-3


CMF C21 H32 N4 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226391-82-8 CAPLUS

CN 4-Piperidinecarboxamide, N-ethyl-1-[4-[[tetrahydro-4-  
[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-81-7


CMF C20 H29 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226391-84-0 CAPLUS


CN Glycine, N-[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-  
yl]sulfonyl]phenyl]-4-piperidinyl]carbonyl]-, mono(trifluoroacetate)  
(salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-83-9

CMF C20 H27 N3 O8 S






CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226391-86-2 CAPLUS


CN L-Histidine, N-[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]carbonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226391-85-1

CMF C24 H31 N5 O8 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 226391-88-4 CAPLUS  
CN 4-Piperidinecarboxamide, N-hydroxy-1-[4-[[tetrahydro-4-  
[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 226391-87-3  
CMF C18 H25 N3 O7 S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 226392-04-7 CAPLUS  
CN 4-Piperidinecarboxamide, N,N-dimethyl-1-[4-[[tetrahydro-4-  
[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 226392-03-6  
CMF C20 H29 N3 O6 S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 226392-06-9 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(1-piperidinylcarbonyl)-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 226392-05-8  
 CMF C23 H33 N3 O6 S



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 226392-08-1 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(4-methyl-1-piperazinyl)carbonyl]-1-piperidinyl]phenyl]sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 226392-07-0  
 CMF C23 H34 N4 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-10-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(1-piperazinylcarbonyl)-1-piperidinyl]phenyl]sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-09-2


CMF C22 H32 N4 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-12-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]carbonyl]-, ethyl ester, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-11-6


CMF C26 H37 N3 O8 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-14-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]carbonyl]-, ethyl ester, mono(trifluoroacetate) (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 226392-13-8


CMF C26 H37 N3 O8 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-16-1 CAPLUS

CN 2-Piperidinecarboxylic acid, 1-[[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]carbonyl]-, ethyl ester, mono(trifluoroacetate) (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 226392-15-0


CMF C26 H37 N3 O8 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-34-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)carbonyl]-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-33-2


CMF C28 H41 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-36-5 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[(hexahydro-1H-azepin-1-yl)carbonyl]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-35-4


CMF C24 H35 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226392-52-5 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(3-hydroxy-1-pyrrolidinyl)carbonyl]-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-51-4

CMF C22 H31 N3 O7 S

PAGE 1-A








CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 226392-54-7 CAPLUS  
CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 226392-53-6  
CMF C24 H36 N4 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 226392-56-9 CAPLUS  
 CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(3S)-3-amino-1-pyrrolidinyl]carbonyl]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-55-8

CMF C22 H32 N4 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-58-1 CAPLUS  
 CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(2R,6S)-2,6-dimethyl-4-morpholinyl]carbonyl]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-, rel-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-57-0

CMF C24 H35 N3 O7 S


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-60-5 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-59-2


CMF C27 H39 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226392-62-7 CAPLUS


CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[4-(1-pyrrolidinyl)-1-piperidinyl]carbonyl]-1-piperidinyl]phenyl]sulfonyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 226392-61-6

CMF C27 H40 N4 O6 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-64-9 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-(1-pyrrolidinylcarbonyl)-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-63-8


CMF C22 H31 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-66-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-N-(2,2,2-trifluoroethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-65-0


CMF C20 H26 F3 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-68-3 CAPLUS

CN 4-Piperidinecarboxamide, N-butyl-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-67-2


CMF C22 H33 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-70-7 CAPLUS

CN 4-Piperidinecarboxamide, N,N-di-2-propenyl-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-69-4


CMF C24 H33 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-72-9 CAPLUS

CN 4-Piperidinecarboxamide, N,N-bis[3-(dimethylamino)propyl]-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, tris(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-71-8


CMF C28 H47 N5 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-74-1 CAPLUS

CN 4-Piperidinecarboxamide, N-(1-methylethyl)-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-73-0


CMF C21 H31 N3 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 226392-76-3 CAPLUS


CN 4-Piperidinecarboxamide, N-4-morpholinyl-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-75-2

CMF C22 H32 N4 O7 S






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-78-5 CAPLUS

CN 4-Piperidinecarboxamide, N-(3-pyridinylmethyl)-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226392-77-4


CMF C24 H30 N4 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 226392-80-9 CAPLUS

CN 4-Piperidinecarboxamide, N-cyclohexyl-1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-, mo

<-----User Break----->

RN 226395-08-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(phenylsulfonyl)amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 226395-10-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-1-piperidinyl]phenyl]sulfonyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226395-09-1


CMF C21 H29 N5 O7 S2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 226395-12-6 CAPLUS


CN 2H-Pyran-4-carboxamide, 4-[[4-[4-(acetylamino)-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 226395-13-7 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-  
 [(methylsulfonyl)amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX  
 NAME)




RN 226395-14-8 CAPLUS  
 CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[(cyclohexylamino)carbonyl]amino]-1-  
 piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 226395-16-0 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[(2-  
 methoxyphenyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI)  
 (CA INDEX NAME)




RN 226395-17-1 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-  
 [(phenylamino)carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI) (CA  
 INDEX NAME)




RN 226395-18-2 CAPLUS  
 CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[(2-  
 phenylethyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI)

(CA INDEX NAME)




RN 226395-19-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[(1-methylethyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI)  
(CA INDEX NAME)




RN 226395-21-7 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 226395-22-8 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[(4-methylthiophenyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 226395-24-0 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI)  
(CA INDEX NAME)




RN 226395-25-1 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-(9CI) (CA INDEX NAME)




RN 226395-26-2 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[(phenylmethyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 226395-27-3 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(ethylamino)carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy-(9CI) (CA INDEX NAME)




RN 226395-28-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]-(9CI) (CA INDEX NAME)




RN 226395-29-5 CAPLUS

CN  $\beta$ -Alanine, N-[[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]amino]carbonyl]-, ethyl ester (9CI)  
(CA INDEX NAME)




RN 226395-30-8 CAPLUS

CN Acetic acid, oxo[[1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 226395-31-9 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(diethylamino)carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 226395-32-0 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[[(dimethylamino)carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 226395-33-1 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-[[bis(1-methylethyl)amino]carbonyl]amino]-1-piperidinyl]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)




RN 226395-35-3 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(1-oxo-3-phenylpropyl)amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 226395-36-4 CAPLUS

CN 2H-Pyran-4-carboxamide, tetrahydro-N-hydroxy-4-[[4-[4-[(1-oxo-3-phenyl-2-propenyl)amino]-1-piperidinyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 226395-37-5 CAPLUS

CN Carbamic acid, [1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidinyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 226395-38-6 CAPLUS

CN Carbamic acid, [1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidiny]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 226395-39-7 CAPLUS

CN Carbamic acid, [1-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenyl]-4-piperidiny]-, 2,2,2-trichloroethyl ester (9CI) (CA INDEX NAME)



RN 226395-40-0 CAPLUS

CN 2H-Pyran-4-carboxamide, 4-[[4-[4-(butylamino)-1-piperidiny]phenyl]sulfonyl]tetrahydro-N-hydroxy- (9CI) (CA INDEX NAME)



=>